59.98
0.00 (0.00%)
| Penutupan Terdahulu | 59.98 |
| Buka | 59.98 |
| Purata Dagangan (3B) | 1,640,071 |
| Modal Pasaran | 2,341,960,960 |
| Harga / Buku (P/B) | 8.51 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 7 Nov 2024 |
| EPS Cair (TTM) | -2.25 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1.36% |
| Nisbah Semasa (MRQ) | 15.97 |
| Aliran Tunai Operasi (OCF TTM) | -65.93 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -36.37 M |
| Pulangan Atas Aset (ROA TTM) | -30.72% |
| Pulangan Atas Ekuiti (ROE TTM) | -46.66% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Longboard Pharmaceuticals, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 0.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 1.0 |
| Purata | 0.25 |
|
Longboard Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. The company is working to improve a portfolio of centrally acting product candidates designed to be selective for specific G protein-coupled receptors (GPCRs). The company is evaluating LP352, an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with negligible observed impact on 5-HT2B and 5-HT2A receptor subtypes, in development for the potential treatment of seizures associated with a broad range of developmental and epileptic encephalopathies. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 1.20% |
| % Dimiliki oleh Institusi | 121.42% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 60.00 (Truist Securities, 0.03%) | Pegang |
| 60.00 (HC Wainwright & Co., 0.03%) | Pegang | |
| 60.00 (B. Riley Securities, 0.03%) | Pegang | |
| Median | 60.00 (0.03%) | |
| Purata | 60.00 (0.03%) | |
| Jumlah | 3 Pegang | |
| Harga Purata @ Panggilan | 59.05 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 15 Oct 2024 | 60.00 (0.03%) | Pegang | 59.08 |
| Truist Securities | 15 Oct 2024 | 60.00 (0.03%) | Pegang | 59.08 |
| B. Riley Securities | 14 Oct 2024 | 60.00 (0.03%) | Pegang | 58.99 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |